Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Circulating endothelial progenitor cells and chronic pulmonary diseases

A. Huertas, P. Palange
European Respiratory Journal 2011 37: 426-431; DOI: 10.1183/09031936.00034810
A. Huertas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Palange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paolo.palange@uniroma1.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Circulating endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular healing and remodelling under physiological and pathological conditions. Although controversies exist regarding the definition and origin of EPCs, it has been widely demonstrated that they are involved in several diseases and that they have therapeutic implications.

Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible, associated with abnormalities of airways (bronchitis) and parenchyma (emphysema), reduced exercise tolerance and systemic inflammation.

Growing evidence has also suggested that endothelial dysfunction may play a role in COPD. Although it is not clear whether endothelial dysfunction represents a cause or a consequence of COPD, several studies have highlighted the importance of EPCs in this disease, suggesting that the bone marrow could be a novel target of COPD.

The present review summarises the role of EPCs in pulmonary diseases, with particular emphasis on COPD. The aim is to improve understanding as to the possible role of EPCs in COPD pathophysiology. This may help in the identification of novel diagnostic and therapeutic tools in COPD.

  • Chronic obstructive pulmonary disease
  • endothelium

In 1997, Asahara et al. 1 first described the differentiation of adult haemopoietic progenitor cells into an endothelial phenotype. In 1998, Shi et al. 2 showed that genetically tagged transplanted bone marrow cells were covering implanted grafts. These pioneering studies suggested the presence of circulating angioblasts in the adult peripheral blood. Since the late 1990s, circulating haemopoietic and endothelial progenitor cells (EPCs) have been studied in order to characterise and understand their role in the pathophysiology of various diseases. Accumulating evidence has shown that circulating EPCs contribute to vascular healing and remodelling under physiological and pathological conditions. Despite some controversies still existing with respect to the identification and origin of these progenitor cells, increasing evidence suggests that these bone marrow-derived cells play an important role in diseases, such as cardiovascular and cerebrovascular, endocrinological, haematological and connective tissue disorders 3. Plasma levels of these circulating EPCs have been seen to correlate with disease severity and risk factors 4. In contrast to the conventional assumption that damaged organs are repaired only by migration and proliferation of adjacent cells, increasing evidence suggests that ectopic progenitor cells are mobilised into the systemic circulation and recruited to the site of tissue regeneration. Furthermore, EPCs also seem to have therapeutic value in coronary artery diseases, increasing neovascularisation of tissue following ischaemia 5–7 and contributing to re-endothelialisation after endothelial injury 8, 9.

The aims of the present review are, first, to provide a state-of-the-art overview of circulating EPCs and pulmonary diseases, with particular emphasis on chronic obstructive pulmonary disease (COPD) and emphysema, and then to present recent findings in the field, which may have implications for diagnostic tools and novel therapeutic strategies in chronic lung diseases.

CIRCULATING EPCS

Definition

In 1997, Asahara et al. 1 showed that purified CD34+ haemopoietic EPCs from human peripheral blood could differentiate into endothelial cells (ECs) in vitro 1. These so-called endothelial progenitor cells (EPCs) showed expression of various EC markers and migrated to sites of active angiogenesis in several animal models. This behaviour suggested that they might be useful for targeted delivery of therapeutic agents that stimulate or inhibit angiogenesis. Until that moment, production of new blood vessels in adults had been thought to result exclusively from the proliferation, migration and remodelling of fully differentiated ECs derived from pre-existing blood vessels 10, 11. According to this initial discovery, EPCs were defined as cells positive for both haemopoietic stem cell markers, such as CD34, and an endothelial marker protein, such as kinase insert domain receptor (also known as vascular endothelial growth factor (VEGF) receptor (VEGFR) 2). Since CD34 was not found exclusively on haemopoietic stem cells, but also on mature ECs, several authors used the more immature haemopoietic stem cell marker CD133 (or AC133) to define EPCs 12, 13. Principle amongst the defining criteria of these endothelioid cells are the presence/absence of the cell surface glycoproteins CD34 (a marker of haematopoietic progenitor cells) 14, 15, CD31, CD146/P1H12 (also frequently used to define circulating ECs), AC133 and fetal liver kinase-1 (another VEGFR), Bandeirara simplicifolia lectin 1 binding, the uptake of acetylated low-density lipoprotein–cholesterol, the presence of von Willebrand factor and in vitro morphology 2, 16, 17. Despite this definition, controversies still exist regarding the identification and origin of the EPCs isolated from peripheral blood mononuclear cells. As recently reviewed by Urbich and Dimmeler 18, several sources of ECs may exist: 1) the rare haemopoietic stem cells; 2) myeloid cells which may differentiate in vitro to ECs; 3) other circulating progenitor cells, such as adult bone marrow-derived stem/progenitor cells (e.g. side-population cells and multipotent adult progenitor cells) 19, 20; 4) circulating mature ECs 21; 5) cells not derived from bone marrow, which have been seen to replace ECs in grafts 22; and 6) tissue-resident stem cells 23.

In 2011, more than ten years after the first description of circulating EPCs, more specific phenotypes are still needed. Hopefully, more surface markers or better profiling of distinct cell populations will soon help to define those cells.

Role in diseases

Despite the difficulties in defining and characterising circulating ECs, increasing evidence suggests that bone marrow-derived cells play an important role in diseases, such as cardiovascular and cerebrovascular, endocrinological, haematological and connective tissue disorders 3. Circulating EPCs are decreased in number and show decreased function in patients with chronic heart failure 24, stroke 25 insulin-dependent 26 and non-insulin-dependent diabetes 27, rheumatoid arthritis 28 and chronic renal failure 29–31. Acute ischaemia is known to mobilise EPCs, as recently reported in patients with acute myocardial infarction 32–34 and unstable angina 35. These data suggest that EPCs are physiologically important in maintaining vascular integrity. Interestingly, EPC numbers are decreased in chronic diseases characterised by increased cardiovascular risk, perhaps due to progressive exhaustion of repair capabilities. It is also known that circulating EPC numbers decrease as the number of cardiovascular risk factors increase; patients with coronary artery disease have a lower number of EPCs than healthy controls, 36–39. These authors also reported that numbers of EPCs correlated inversely with the number of risk factors. Similarly, in males free of a history of clear atherosclerosis, Hill et al. 40 reported an inverse correlation between EPC numbers and the Framingham risk factor score, and between EPC numbers and macrovascular function, as assessed by flow-mediated dilatation.

In cardiovascular diseases, the finding that bone marrow-derived cells can migrate to sites of ischaemia and express endothelial surface markers has introduced the challenge of a role for EPCs for therapeutic use. These cells have been shown to actively promote vascular repair, mainly through two mechanisms: neovascularisation, and endothelial regeneration. Several experimental and clinical studies have been performed with different improvement models, demonstrating the possible therapeutic importance of EPCs 6, 7, 9, 41–44. Statins 36, 45 and angiotensin II receptor antagonists 46 have been seen to partly restore the decreased number of EPCs. Autologous EPCs have been used to improve vascularisation of myocardium or lower limbs in patients with acute myocardial infarction 7 and animals with experimentally induced arterial lesions 47. In both cases, vascularisation improved and tissue damage was reduced following treatment. Regular exercise training has also been shown to augment the number of circulating EPCs in patients with cardiovascular risk factors and coronary artery disease, and is associated with improved vascular function and nitric oxide synthesis 48.

CIRCULATING PROGENITOR CELLS AND LUNG DISEASES

Despite this understanding, little is known about circulating EPCs in lung diseases (table 1). To date, in asthma, for example, Stirling et al. 49 have reported that systemic interleukin (IL)-5 increased circulating eosinophil progenitor numbers, suggesting a key role for systemic IL-5 in eosinophil mobilisation. It is known that the inflammation of chronic asthma is associated with activation of peripheral blood T-lymphocytes and eosinophils and subsequent infiltration of these cells into the airway 61; in particular, type-2 T-helper cells, source of IL-5, are increased in the asthmatic airway 62. IL-5 levels have been measured in the circulation of asthmatic individuals 63, rise during asthma exacerbations 64 and play an important role in the mobilisation, terminal differentiation and maintenance of mature eosinophils 65. It has been shown that mature eosinophils develop from pluripotent haematopoietic progenitor cells that express the cell surface glycoprotein CD34 50. Increased numbers of CD34+ cells have been demonstrated in both blood and bone marrow from atopic individuals as compared with normal subjects 51, and in the bronchial mucosa of atopic asthmatic subjects 66. These findings underlie the central role of IL-5, confirming the data of O’Byrne et al. 67 on the mobilisation of eosinophil precursors (CD34+/CD45+ progenitors) into the peripheral blood, and that systemic rather than airway IL-5 activity may be more potent in this role.

View this table:
  • View inline
  • View popup
Table 1– Comparison of the main roles of circulating endothelial progenitor cells (EPCs) in lung diseases

In pulmonary diseases in which endothelial dysfunction represents a key part of the pathophysiology, growing evidence is showing the importance of EPCs. In idiopathic and associated pulmonary arterial hypertension (PAH), clinical studies have suggested a link between EPC count and PAH severity, but with controversial results, as recently reviewed elsewhere 52. In experimental studies, EPC numbers are increased in hypoxia-induced PAH because of compensatory mobilisation and recruitment mechanisms. As a therapeutic tool, infusion of EPCs seems promising in monocrotaline-induced PAH, but further investigations are required for a better understanding.

Chronic obstructive pulmonary disease

EPCs may also be involved in COPD, but little is known about their role in chronic bronchitis and emphysema. COPD is also frequently associated with abnormalities in the pulmonary circulation, leading to pulmonary hypertension and right ventricular failure, with a greater mortality risk 68. PAH in COPD occurs due to alterations in pulmonary vessel structure (intimal hyperplasia of muscular arteries and muscularisation of small arterioles) 69. Intimal hyperplasia is produced by the proliferation of poorly differentiated smooth muscle cells and the deposition of collagen and elastic fibres 69. The molecular mechanism of mobilisation, homing and differentiation of putative smooth-muscle-like progenitor cells remains to be clarified. Since endothelium plays a key role in regulating cell growth in the vessel wall, it has been hypothesised that endothelial dysfunction might be an initiating event that promotes vessel remodelling and PAH in COPD 68. However, the pathobiology of pulmonary vascular remodelling in COPD is not fully understood and it remains unclear whether endothelial-like cells and smooth-muscle-like cells differentiate from a common vascular progenitor cell. Several animal and clinical studies have demonstrated that transplantation of autologous EPCs or unfractionated bone marrow cells facilitates vascular repair 8, 70. Conversely, others have suggested that circulating EPCs could participate not only in maintenance of vascular homeostasis but also in the pathogenesis of various diseases, by inducing smooth muscle cell proliferation and neointimal formation at sites of vascular injury 71–74. Peinado et al. 53 showed the presence of vascular progenitor cells (VPCs) adhered to the endothelial surface and within the intimal layer in pulmonary arteries of COPD patients. The presence of VPCs in the vicinity of areas of endothelial denudation and their relation with the response to hypoxic stimulus suggested that these cells might contribute to an ongoing process of endothelial repair. The authors also described an increased number of VPCs in the intima of pulmonary arteries, which was associated with the enlargement of the vessel wall. The latter finding suggests that VPCs could also be involved in the pathogenesis of intimal hyperplasia, presumably through VEGF-related signals.

Furthermore, Tuder et al. 75 and Kasahara et al. 76 have shown that emphysema is associated with decreased lung expression of VEGF and its receptor VEGFR-2 in animal models. Therefore, it is reasonable to assume that EPCs might be involved in COPD pathogenesis and that the bone marrow could be a new target of COPD. It has been shown that 13% of COPD patients have anaemia associated with increased systemic inflammatory marker levels 77, 78, but few data are available regarding other cell lineages, despite neutrophil activation and increased smoke-related turnover of granulocytes 79. Increasing evidence from our group, confirmed by others, is showing that circulating progenitor cells are involved in COPD and correlate with disease severity. It has been demonstrated that circulating haemopoietic progenitor cell numbers are greatly decreased at rest, do not increase after endurance exercise and correlate with the level of hypoxaemia, severity of airway obstruction and peak oxygen uptake in COPD patients 59. These data suggest a possible involvement of EPCs in the pathogenesis of decreased exercise capacity. In particular, COPD patients may show decreased capability for repair or angiogenesis of skeletal muscle due to a reduction in the number of circulating CD34+ cells, perhaps secondary to excessive peripheral utilisation of these cells or activation of apoptosis. CD34+ cells were also shown to be involved in tissue repair in skeletal muscle: 1) CD34+ cells are able to migrate to muscular connective tissue 80; and 2) in a murine model, the percentage of these progenitor cells increased in muscle fibres when animals were kept active (running wheel in the cage) 81, suggesting that CD34+ cells were capable of substituting skeletal muscle. Data have also been published on athletes, showing that circulating CD34+ cell counts were higher in runners than in sedentary subjects, but decreased on the day following a marathon race, in agreement with their possible utilisation in skeletal muscle for repair purposes 82. Furthermore, the hypothesis that the type of exercise and fitness level could modulate cytokine/growth factor release has also been tested; indeed, it was found that all-out exercise in well-trained rowers acutely mobilised haematopoietic progenitor cells, T- and natural killer lymphocytes and immature reticulocytes, suggesting that progenitor cell mobilisation may occur in response to tissue hypoxia, or signals originating in skeletal muscle at a very high workload 83. The lung could represent another hypothetical target for circulating EPCs in COPD patients. Examination of lung tissue from COPD patients revealed the presence of apoptotic cells in greater number than in control lungs or those from smokers without COPD 76. Apoptotic cells included alveolar and bronchial epithelial cells, as well as ECs in the parenchyma. Importantly, the apoptosis persisted in patients with COPD after smoking had ceased 60. It could be hypothesised that the excessive lung utilisation of circulating EPCs, in response to cell apoptosis, led to a decreased number of circulating EPCs (fig. 1). Further studies are still required in order to elucidate the targets of the circulating EPCs.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Bone marrow response to endothelial damage in: a) normal subjects; and b) chronic obstructive pulmonary disease patients: potential mechanisms and consequences. VEGF: vascular endothelial growth factor; VLA: very late antigen; CCR: CC chemokine receptor; CXCR: CXC chemokine receptor; EPC: endothelial progenitor cell; TNF: tumour necrosis factor; IL: interleukin.

As for the mobilisation and homing of EPCs, it is possible that inflammatory processes, occurring in COPD (neutrophil activation and oxidative stress), or tissue hypoxia may be involved in the decrease in circulating CD34+ cell numbers, but little is known regarding possible associations between circulating CD34+ cells and pro-inflammatory mediators in COPD. In severe COPD patients who displayed a low body mass index (BMI), the bone marrow appears insufficiently stimulated despite higher plasma growth factor concentrations 84. Therefore, it is reasonable to speculate that the bone marrow could be inhibited by myelosuppressive cytokines, such as tumour necrosis factor-α, leading to reduced regenerative capacity. It has recently been shown that disease severity correlated with pro-angiogenetic and inflammatory marker levels and was inversely associated with circulating EPC numbers 84. Furthermore, among patients with similar pulmonary impairment, those who displayed a low BMI had a more markedly reduced number of circulating EPCs. The findings also indicate that, in severe low-BMI COPD patients, bone marrow function seems to be further impaired and may lead to reduced reparative capacity. The systemic involvement of COPD, characterised by systemic inflammation, malnutrition and skeletal muscle dysfunction, may indicate exhaustion of repair and/or angiogenetic resources (fig. 1) 85.

CONCLUSION

As revealed in the present review, several potential uses of bone marrow-derived circulating EPCs are indicated. The regulation of EPC homing, differentiation and proliferation remains unclear and requires greater understanding, in particular in chronic lung diseases, in order to achieve optimal therapeutic benefits. As for cardiovascular diseases, therapeutic utilisation of EPCs might also be extended to COPD in the future.

More studies are needed to understand the pathophysiology of chronic lung diseases, such as COPD, particularly regarding the systemic involvement of the disease.

Footnotes

  • Statement of Interest

    None declared.

  • Received March 4, 2010.
  • Accepted June 16, 2010.
  • ©ERS 2011

REFERENCES

  1. ↵
    1. Asahara T,
    2. Murohara T,
    3. Sullivan A,
    4. et al
    . Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–967.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Shi Q,
    2. Rafii S,
    3. Wu MH,
    4. et al
    . Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362–367.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Blann AD,
    2. Pretorius A
    . Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? Atherosclerosis 2006; 188: 12–18.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Vasa M,
    2. Fichtlscherer S,
    3. Aicher A,
    4. et al
    . Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1–E7.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Kawamoto A,
    2. Gwon HC,
    3. Iwaguro H,
    4. et al
    . Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634–637.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kocher AA,
    2. Schuster MD,
    3. Szabolcs MJ,
    4. et al
    . Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–436.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Assmus B,
    2. Schächinger V,
    3. Teupe C,
    4. et al
    . Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009–3017.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Walter DH,
    2. Rittig K,
    3. Bahlmann FH,
    4. et al
    . Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017–3024.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Werner N,
    2. Junk S,
    3. Laufs U,
    4. et al
    . Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: e17–e24.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Schaper W,
    2. De Brabander M,
    3. Lewi P
    . DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res 1971; 28: 671–679.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Folkman J,
    2. Shing Y
    . Angiogenesis. J Biol Chem 1992; 267: 10931–10934.
    OpenUrlFREE Full Text
  12. ↵
    1. Peichev M,
    2. Naiyer AJ,
    3. Pereira D,
    4. et al
    . Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952–958.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Gehling UM,
    2. Ergün S,
    3. Schumacher U,
    4. et al
    . In vitro differentiation of endothelial cells from AC133-positive progenitors cells. Blood 2000; 95: 3106–3112.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Berenson RJ,
    2. Andrews RG,
    3. Bensinger WI,
    4. et al
    . Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951–955.
    OpenUrlPubMedWeb of Science
  15. ↵
    1. Vaughan WP,
    2. Civin CI,
    3. Weisenburger DD,
    4. et al
    . Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia 1988; 2: 661–666.
    OpenUrlPubMedWeb of Science
  16. ↵
    1. Ikpeazu C,
    2. Davidson MK,
    3. Halteman D,
    4. et al
    . Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantation. Biol Blood Marrow Transpl 2000; 6: 301–308.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Quirici N,
    2. Soligo D,
    3. Caneva L,
    4. et al
    . Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells. Br J Haematol 2001; 115: 186–194.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Urbich C,
    2. Dimmeler S
    . Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343–353.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Jackson KA,
    2. Majka SM,
    3. Wang H,
    4. et al
    . Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395–1402.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Reyes M,
    2. Dudek A,
    3. Jahagirdar B,
    4. et al
    . Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337–346.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Mutin M,
    2. Canavy I,
    3. Blann A,
    4. et al
    . Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951–2958.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hillebrands JL,
    2. Klatter FA,
    3. van Dijk WD,
    4. et al
    . Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med 2002; 8: 194–195.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Beltrami AP,
    2. Barlucchi L,
    3. Torella D,
    4. et al
    . Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763–776.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Valgimigli M,
    2. Rigolin GM,
    3. Fucili A,
    4. et al
    . CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209–1212.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Ghani U,
    2. Shuaib A,
    3. Salam A,
    4. et al
    . Endothelial progenitor cells during cerebrovascular disease. Stroke 2005; 36: 151–153.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Loomans CJ,
    2. de Koning EJ,
    3. Staal FJ,
    4. et al
    . Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53: 195–199.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Tepper OM,
    2. Galiano RD,
    3. Capla JM,
    4. et al
    . Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781–2786.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Grisar J,
    2. Aletaha D,
    3. Steiner CW,
    4. et al
    . Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111: 204–211.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. de Groot K,
    2. Bahlmann FH,
    3. Sowa J,
    4. et al
    . Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641–646.
    OpenUrlCrossRefPubMedWeb of Science
    1. Choi JH,
    2. Kim KL,
    3. Huh W,
    4. et al
    . Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004; 24: 1246–1252.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Eizawa T,
    2. Murakami Y,
    3. Matsui K,
    4. et al
    . Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 2003; 19: 627–633.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Shintani S,
    2. Murohara T,
    3. Ikeda H,
    4. et al
    . Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776–2779.
    OpenUrlAbstract/FREE Full Text
    1. Massa M,
    2. Rosti V,
    3. Ferrario M,
    4. et al
    . Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005; 105: 199–206.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Leone AM,
    2. Rutella S,
    3. Bonanno G,
    4. et al
    . Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005; 26: 1196–1204.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. George J,
    2. Goldstein E,
    3. Abashidze S,
    4. et al
    . Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 2004; 25: 1003–1008.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Vasa M,
    2. Fichtlscherer S,
    3. Adler K,
    4. et al
    . Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885–2890.
    OpenUrlAbstract/FREE Full Text
    1. Adams V,
    2. Lenk K,
    3. Linke A,
    4. et al
    . Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 2004; 24: 684–690.
    OpenUrlAbstract/FREE Full Text
    1. Eizawa T,
    2. Ikeda U,
    3. Murakami Y,
    4. et al
    . Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart 2004; 90: 685–686.
    OpenUrlFREE Full Text
  35. ↵
    1. Werner N,
    2. Kosiol S,
    3. Schiegl T,
    4. et al
    . Circulating endothelial progenitor cells and cardiovascular outcome. N Engl J Med 2005; 353: 999–1007.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Hill JM,
    2. Zalos G,
    3. Halcox JP,
    4. et al
    . Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med 2003; 348: 593–600.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Ince H,
    2. Petzsch M,
    3. Kleine HD,
    4. et al
    . Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005; 112: 3097–3106.
    OpenUrlAbstract/FREE Full Text
    1. Minamino K,
    2. Adachi Y,
    3. Okigaki M,
    4. et al
    . Macrophage colony-stimulating factor (M-CSF), as well as granulocyte colony-stimulating factor (G-CSF), accelerates neovascularization. Stem Cells 2005; 23: 347–354.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kang HJ,
    2. Lee HY,
    3. Na SH,
    4. et al
    . Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction. The MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006; 114: Suppl. 1, I145–I151.
    OpenUrlPubMedWeb of Science
  38. ↵
    1. Takamiya M,
    2. Okigaki M,
    3. Jin D,
    4. et al
    . Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/Flk-1+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2006; 26: 751–757.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Dimmeler S,
    2. Aicher A,
    3. Vasa M,
    4. et al
    . HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391–397.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Bahlmann FH,
    2. de Groot K,
    3. Mueller O,
    4. et al
    . Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526–529.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Tateishi-Yuyama E,
    2. Matsubara H,
    3. Murohara T,
    4. et al
    . Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427–435.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Steiner S,
    2. Niessner A,
    3. Ziegler S,
    4. et al
    . Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305–310.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Stirling RG,
    2. van Rensen EL,
    3. Barnes PJ,
    4. et al
    . Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med 200;164: 1403–1409.
  44. ↵
    1. Shalit M,
    2. Sekhsaria S,
    3. Mauhorter S,
    4. et al
    . Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis. J Allergy Clin Immunol 1996; 98: 344–354.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Sehmi R,
    2. Howie K,
    3. Sutherland DR,
    4. et al
    . Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects. Am J Respir Cell Mol Biol 1996; 15: 645–655.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Fadini GP,
    2. Avogaro A,
    3. Ferraccioli G,
    4. et al
    . Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J 2010; 35: 418–425.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Peinado VI,
    2. Ramírez J,
    3. Roca J,
    4. et al
    . Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006; 34: 257–263.
    OpenUrlCrossRefPubMedWeb of Science
    1. Asosingh K,
    2. Aldred MA,
    3. Vasanji A,
    4. et al
    . Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008; 172: 615–627.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Davie NJ,
    2. Crossno JT Jr.,
    3. Frid MG,
    4. et al
    . Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L668–L678.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Junhui Z,
    2. Xingxiang W,
    3. Guosheng F,
    4. et al
    . Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med 2008; 102: 1073–1079.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Raoul W,
    2. Wagner-Ballon O,
    3. Saber G,
    4. et al
    . Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice. Respir Res 2007; 8: 8.
  51. ↵
    1. Marsboom G,
    2. Pokreisz P,
    3. Gheysens O,
    4. et al
    . Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells 2008; 26: 1017–1026.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Palange P,
    2. Testa U,
    3. Huertas A,
    4. et al
    . Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006; 27: 529–541.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Hodge S,
    2. Hodge G,
    3. Holmes M,
    4. et al
    . Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005; 25: 447–454.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Corrigan CJ,
    2. Kay AB
    . T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992; 13: 501–507.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Robinson DS,
    2. Hamid Q,
    3. Ying S,
    4. et al
    . Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298–304.
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    1. Alexander AG,
    2. Barkans J,
    3. Moqbel R,
    4. et al
    . Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Thorax 1994; 49: 1231–1233.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Corrigan CJ,
    2. Haczku A,
    3. Gemou-Engesaeth V,
    4. et al
    . CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5: effect of glucocorticoid therapy. Am Rev Respir Dis 1993; 147: 540–547.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Kotsimbos AT,
    2. Hamid Q
    . IL-5 and IL-5 receptor in asthma. Mem Inst Oswaldo Cruz 1997; 92: Suppl. 2, 75–91.
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Robinson DS,
    2. Damia R,
    3. Zeibecoglou K,
    4. et al
    . CD34+/interleukin-5Rα messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am J Respir Cell Mol Biol 1999; 20: 9–13.
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. O’Byrne PM,
    2. Gauvreau GM,
    3. Wood LJ
    . Interaction between haemopoietic regulation and airway inflammation. Clin Exp Allergy 1999; 29: Suppl. 2, 27–32.
    OpenUrl
  61. ↵
    1. Santos S,
    2. Peinado VI,
    3. Ramírez J,
    4. et al
    . Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632–638.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Barbera JA,
    2. Peinado VI,
    3. Santos S
    . Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892–905.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Khakoo AY,
    2. Finkel T
    . Endothelial progenitor cells. Annu Rev Med 2005; 56: 79–101.
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    1. Saiura A,
    2. Sata M,
    3. Hirata Y,
    4. et al
    . Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001; 7: 382–383.
    OpenUrlCrossRefPubMedWeb of Science
    1. Sata M,
    2. Saiura A,
    3. Kunisato A,
    4. et al
    . Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403–409.
    OpenUrlCrossRefPubMedWeb of Science
    1. Shimizu K,
    2. Sugiyama S,
    3. Aikawa M,
    4. et al
    . Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738–741.
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    1. Werner N,
    2. Priller J,
    3. Laufs U,
    4. et al
    . Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22: 1567–1572.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Tuder RM,
    2. Zhen L,
    3. Cho CY,
    4. et al
    . Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88–97.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Kasahara Y,
    2. Tuder RM,
    3. Cool CD,
    4. et al
    . Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001; 163: 737–744.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    1. John M,
    2. Hoernig S,
    3. Doehner W,
    4. et al
    . Anemia and inflammation in COPD. Chest 2005; 127: 825–829.
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    1. Chambellan A,
    2. Chailleux E,
    3. Similowski T,
    4. et al
    . Prognostic values of hematocrit in patients with chronic obstructive pulmonary disease receiving long term oxygen therapy. Chest 2005; 128: 1201–1208.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. van Eeden SF,
    2. Hogg JC
    . The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000; 15: 915–921.
    OpenUrlAbstract
  71. ↵
    1. Dreyfus PA,
    2. Chretien F,
    3. Chazaud B,
    4. et al
    . Adult bone-marrow-derived stem cells in muscle connective tissue and satellite niches. Am J Pathol 2004; 164: 773–779.
    OpenUrlPubMedWeb of Science
  72. ↵
    1. LaBarge MA,
    2. Blau HM
    . Biological progression from adult bone marrow to mononucleate muscle stem cells to multinucleate muscle fiber in response to injury. Cell 2002; 111: 589–601.
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Bonsignore MR,
    2. Morici G,
    3. Santoro A,
    4. et al
    . Circulating hematopoietic progenitor cells in runners. J Appl Physiol 2002; 93: 1691–1697.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Morici G,
    2. Zangla D,
    3. Santoro A,
    4. et al
    . Supramaximal exercise mobilizes hematopoietic progenitors and reticulocytes in athletes. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1496–R1503.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Huertas A,
    2. Testa U,
    3. Riccioni R,
    4. et al
    . Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respir Physiol Neurobiol 2010; 170: 23–31.
    OpenUrlCrossRefPubMedWeb of Science
  76. ↵
    1. Agustí AG,
    2. Sauleda J,
    3. Miralles C,
    4. et al
    . Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485–489.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 37 Issue 2 Table of Contents
European Respiratory Journal: 37 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Circulating endothelial progenitor cells and chronic pulmonary diseases
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Circulating endothelial progenitor cells and chronic pulmonary diseases
A. Huertas, P. Palange
European Respiratory Journal Feb 2011, 37 (2) 426-431; DOI: 10.1183/09031936.00034810

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Circulating endothelial progenitor cells and chronic pulmonary diseases
A. Huertas, P. Palange
European Respiratory Journal Feb 2011, 37 (2) 426-431; DOI: 10.1183/09031936.00034810
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • CIRCULATING EPCS
    • CIRCULATING PROGENITOR CELLS AND LUNG DISEASES
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Mechanisms of lung disease
  • Lung biology and experimental studies
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The physiological basis of pulmonary arterial hypertension
  • The role of circular RNAs in pulmonary hypertension
  • The paradox of immune checkpoint inhibition reactivating tuberculosis
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society